SK Bioscience Licenses CDC Rotavirus Vaccine Technology for Global Immunization

SK Bioscience has secured a license for rotavirus vaccine technology from the Centers for Disease Control and Prevention. This agreement aims to significantly advance global immunization efforts against the rotavirus disease. The technology transfer will enable SK Bioscience to manufacture and distribute the vaccine more widely. Rotavirus remains a leading cause of severe diarrhea in young children globally. Access to this technology is expected to improve vaccine availability in underserved regions. The partnership highlights a commitment to public health through international scientific collaboration. SK Bioscience plans to utilize its production capabilities to scale up the supply of this critical vaccine. This move supports broader global health initiatives to reduce child mortality and morbidity rates.